Unlocking our innate potential for antitumor immunity

Vaxiion's recombinant bacterial minicells (rBMCs) are small spherical nano-sized bacterial particles that contain all of the molecular components of parental bacteria except the bacterial chromosome. Without chromosomes, rBMCs are replication incompetent, making them highly suitable for development as in vivo targeted delivery products

VAX014 is a novel pan-solid tumor-targeted oncolytic immunotherapy based on rBMCs designed to have distinctly disruptive advantages over virus-based oncolytic agents. Vaxiion is leveraging these advantages to develop VAX014 as a best-in-class oncolytic treatment modality that facilitates antitumor immune responses through in situ immunization. The result is a considerably more effective, user friendly, and more accessible alternative to oncolytic virus-based therapies

In situ  immunization (ISI) is an attractive method of generating polyclonal patient-specific "personalized" T-cell mediated antitumor responses and protective immunologic memory. Unlike current autologous T cell therapies, this simple approach circumvents the time, cost, and complexity of having to harvest, amplify, and reintroduce patient-specific T cells from other sources.